Results 21 to 30 of about 35,228 (288)

Patient-derived tumor organoids for cancer immunotherapy: culture techniques and clinical application. [PDF]

Invest New Drugs
Cancer immunotherapy has revolutionized tumor treatment. However, robust and effective testing platforms remain lacking, especially for the selection of the optimized therapy at the patient-specific level. Unlike conventional treatment evaluations, testing platforms for cancer immunotherapy must incorporate not only tumor cells but also the tumor ...
Yao N, Jing N, Lin J, Niu W, Yan W, Yuan H, Xiong Z, Hou Q, Qiao X, Liu Q, Cao J, Li N.   +11 more
europepmc   +3 more sources

Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity

Neuro-Oncology Advances, 2023
Abstract Background Treatment resistance and tumor relapse are the primary causes of mortality in glioblastoma (GBM), with intratumoral heterogeneity playing a significant role. Patient-derived cancer organoids have emerged as a promising model capable of recapitulating tumor heterogeneity.
Verduin, Maikel, Hoosemans, Linde, Vanmechelen, Maxime, van Heumen, Mike, Piepers, Jolanda A.F., Astuti, Galuh, Ackermans, Linda, Schijns, Olaf E.MG., Kampen, Kim R., Tjan-Heijnen, Vivianne C.G., de Barbanson, Buys A., Postma, Alida A., Eekers, Danielle B.P., Broen, Martijn P.G., Beckervordersandforth, Jan, Stankova, Katerina, de Smet, Frederik, Rich, Jeremy, Hubert, Christopher G., Gimenez, Gregory, Chatterjee, Aniruddha, Hoeben, Ann, Vooijs, Marc A.   +22 more
openaire   +6 more sources

Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids. [PDF]

Int J Mol Sci, 2021
Choi SY, Cho YH, Kim DS, Ji W, Choi CM, Lee JC, Rho JK, Jeong GS.   +7 more
europepmc   +2 more sources

Multi-omic dataset of patient-derived tumor organoids of neuroendocrine neoplasms. [PDF]

Gigascience, 2023
AbstractBackgroundOrganoids are three-dimensional experimental models that summarize the anatomical and functional structure of an organ. Although a promising experimental model for precision medicine, patient-derived tumor organoids (PDTOs) have currently been developed only for a fraction of tumor types.ResultsWe have generated the first multi-omic ...
Alcala N, Voegele C, Mangiante L, Sexton-Oates A, Clevers H, Fernandez-Cuesta L, Dayton TL, Foll M.   +7 more
europepmc   +5 more sources

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance [PDF]

Biomedicines, 2021
The development of patient-derived tumor organoids (TOs) from an epithelial ovarian cancer tumor obtained at the time of primary or interval debulking surgery has the potential to play an important role in precision medicine. Here, we utilized TOs to test front-line chemotherapy sensitivity and to investigate genomic drivers of carboplatin resistance ...
Justin W. Gorski, Zhuwei Zhang, J. Robert McCorkle, Jodi M. DeJohn, Chi Wang, Rachel W. Miller, Holly H. Gallion, Charles S. Dietrich, Frederick R. Ueland, Jill M. Kolesar   +9 more
openaire   +3 more sources

Patient-Derived Tumor Organoids: A Platform for Precision Therapy of Colorectal Cancer. [PDF]

Cell Transplant
Colorectal cancer (CRC) represents a significant cause of cancer-related mortality on a global scale. It is a highly heterogeneous cancer, and the response of patients to homogeneous drug therapy varies considerably. Patient-derived tumor organoids (PDTOs) represent an optimal preclinical model for cancer research.
Li Y, Wu W, Yao J, Wang S, Wu X, Yan J.
europepmc   +4 more sources

Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma. [PDF]

Int J Mol Sci, 2022
An obstacle to effective uniform treatment of glioblastoma, especially at recurrence, is genetic and cellular intertumoral heterogeneity. Hence, personalized strategies are necessary, as are means to stratify potential targeted therapies in a clinically relevant timeframe.
Ratliff M, Kim H, Qi H, Kim M, Ku B, Azorin DD, Hausmann D, Khajuria RK, Patel A, Maier E, Cousin L, Ogier A, Sahm F, Etminan N, Bunse L, Winkler F, El-Khoury V, Platten M, Kwon YJ.   +18 more
europepmc   +3 more sources

Uncovering cantharidin's mechanism for cholangiocarcinoma treatment using patient-derived tumor organoids. [PDF]

iScience
Han P, Wang L, Zhu L, Tong W, Liu S, Wang T, Yang T, Li Z, Zhou X, Zhao T, Cui T, Yang L, Wang Z, Zhang Y.   +13 more
europepmc   +2 more sources

MODL-13. Patient-derived organoids for modeling pediatric brain tumors

Neuro-Oncology, 2022
Abstract Central nervous system (CNS) tumors are the most common solid tumors in the pediatric population and the main cause of death among childhood cancers. They present common features related to the development and produce symptoms based on the age of the child, their location and rate of tumor growth.
Chiara Lago, Claudio Ballabio, Evelina Miele, Luca Tiberi   +3 more
openaire   +1 more source

Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response [PDF]

Frontiers in Oncology, 2021
Three-quarters of compounds that enter clinical trials fail to make it to market due to safety or efficacy concerns. This statistic strongly suggests a need for better screening methods that result in improved translatability of compounds during the preclinical testing period.
Erin R. Spiller, Nolan Ung, Seungil Kim, Katherin Patsch, Roy Lau, Carly Strelez, Chirag Doshi, Sarah Choung, Brandon Choi, Edwin Francisco Juarez Rosales, Edwin Francisco Juarez Rosales, Heinz-Josef Lenz, Naim Matasci, Shannon M. Mumenthaler, Shannon M. Mumenthaler   +14 more
openaire   +3 more sources